Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Senior Vice Minister Yamamoto, Parliamentary Secretary Shimamura Responsible for Healthcare
October 8, 2021
- MHLW Publishes Application Statuses for Infertility Treatments
October 7, 2021
- Atsushi Koga, Hiroshi Yamamoto Named Senior Vice Health Ministers
October 7, 2021
- New Digital, Administrative Reform Minister Set to Break Silos, Propel Healthcare Revamp
October 6, 2021
- Economic Security Chief Vows to Beef Up Vaccine Development, Manufacturing in Japan
October 6, 2021
- Master Plan on COVID-19 Measures to Be Compiled Relatively Soon: Response Minister
October 6, 2021
- New Vaccine Czar Hints Booster Program Could Start in December
October 6, 2021
- Transparency and Predictability Up for Discussion towards 2022 Drug Pricing Reform: New Minister
October 6, 2021
- PM Kishida Orders 3 Ministers to Map Out Overall COVID-19 Response Plan
October 5, 2021
- Innovative Drug Makers Log Sluggish Generic Use Rates: MHLW Data
October 5, 2021
- New Health Minister Goto Vows to Protect Secure Healthcare System in FY2022 Reform
October 5, 2021
- Nipocalimab, 3 Other APIs Earn Orphan Status in Japan
October 5, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW Panels
October 4, 2021
- Manabu Yoshida Becomes Vice Health Minister, Top Bureaucrat at MHLW
October 4, 2021
- No Factor to Impede Reinstatement of HPV Vaccine Recommendation: Panels
October 4, 2021
- Govt Must Prepare for Booster Shot Rollout before Year-End: Kono
October 4, 2021
- Ex-PMDA Chief Kondo, Credited with Eliminating Japan’s Drug Lag, Dies at 79
September 30, 2021
- Pharma Officials Air Hopes and Concerns for New LDP Leader, Eyes on MHLW Revamp
September 30, 2021
- GSK’s COVID-19 Drug to Be Allocated through Govt for Now
September 30, 2021
- MHLW Panel to Discuss HPV Vaccine Recommendation on Oct. 1
September 29, 2021
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…